Basel, North West Switzerland
Web: Novartis external link
Lieu: Bâle
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Médecine 24.4
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS -   Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression com
Médecine 21.4

Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.

Médecine 18.4

Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) -   R/r DLBCL, an

Médecine 6.4

Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet med

Médecine 20.4

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia NIH study found 58% of patients with treatment-naïve sev

Médecine 18.4

Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive  form of non-alcoholic fatty liver disease -   There are currently n

Médecine 3.4

New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate in